1. Describe the process used by the SPORE for identifying and selectively funding innovative pilotstudies within and outside of the SPORE institutionBert Vogelstein, MD, will continue to serve as Principal Investigator of this Program. The Program has been amajor focus of the SPORE because it provides for a continuous flow of innovative ideas and activity tostimulate investigation in the context of SPORE translational research. The Developmental Research Programprovides a means to respond to new opportunities, and is designed to encourage and facilitate new researchefforts. The Program takes advantage of the broad expertise of researchers at The Johns Hopkins Universityand of external investigators by providing funds for pilot projects with potential for development into full-fledgedtranslational research avenues, collaborations, and new methodologies for integration into other ResearchProjects. In most prior years, the Cancer Center has augmented the funding provided to each of our pilotproject recipients by approximately 50% per award (on average). In the past two years, the formation of a GlCancer program within the Oncology Center has also provided support for additional basic and clinical pilotprojects that are not intended to be as translational as the goals of the SPORE Developmental Projects. Withinthis year, we also have gained a commitment for an additional two pancreatic cancer pilot projects to befunded by institutional sources each year. These resources, and funding pressures from a reduced overallbudget for the proposed SPORE funding period, have allowed us to shift some of the financial sources fromthe SPORE to the institution, as reflected in the newly proposed Developmental Research Budget.2. Provide a summary identifying the achievements of all projects supported during the last projectperiod. Specifically discuss whether they were promoted to a full project in the SPORE, led to othergrant applications, or were terminated because of lack of success. For ongoing activities during thepast 12 months, report on progress3. Provide brief examples of projects that may be supported during the grant period.It seems premature to speculate on projects that may be supported in the distant future. Good ideas for pilotprojects should ideally find a source of initial support within a 6-month period, and at most by one year. In ourcurrent solicitation, we have favorably evaluated a proposal from Dr. Eshleman to extend his pilot project for asecond year to begin July 2006. We are also considering a new proposal to test a nonabsorbable, orallyadministered antiproliferative agent in patients having had colectomy for Familial Adenomatous Polyposis.4. Provide a description of the process by which projects will be (or have been) promoted to fulltranslational research projects within the SPORE.Two of the past pilot projects were elevated to the status of Research Project, and two became subjects ofSPORE clinical supplemental grants. Elevation to the status of Research Project occurs when a budgetaryopportunity occasions a solicitation for new Research Project(s) in the SPORE; thus, the Pilot is required toout-compete all other alternative projects if it is to become a Research Project. In other words, a successfulpilot can be a means to prepare an application for the SPORE, and the Developmental Research Programremains keenly aware that a successful pilot program can be a potent source of rejuvenation for the SPORE.Budgetary openings represent a limited window of opportunity, and thus a second pathway has also beenmade available, which is to incorporate the best directions of our pilots into our ongoing Research Projects orinto our Cores. It is by this method that the cytogenetics project of Dr. Griffin became a component of ourTissue Core for a number of years, that the studies Dr. Maitra became associated with the current Project 2A(which is the proposed Project 3C, to be co-led by Dr. Maitra), and that the studies of Dr. Pandey becameassociated with the proposed project 3B.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA062924-14
Application #
7246860
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-08-29
Budget End
2008-06-30
Support Year
14
Fiscal Year
2007
Total Cost
$95,139
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Kuboki, Yuko; Fischer, Catherine G; Beleva Guthrie, Violeta et al. (2018) Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. J Pathol :
Zhang, Jiajia; Quadri, Shafat; Wolfgang, Christopher L et al. (2018) New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. Biomedicines 6:
Hata, Tatsuo; Suenaga, Masaya; Marchionni, Luigi et al. (2018) Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. Am J Pathol 188:1723-1733
Noë, Michaël; Rezaee, Neda; Asrani, Kaushal et al. (2018) Immunolabeling of Cleared Human Pancreata Provides Insights into Three-Dimensional Pancreatic Anatomy and Pathology. Am J Pathol 188:1530-1535
Schunke, Kathryn J; Rosati, Lauren M; Zahurak, Marianna et al. (2018) Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers. Adv Radiat Oncol 3:42-51
Zhang, Jiajia; Wolfgang, Christopher L; Zheng, Lei (2018) Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. Cancers (Basel) 10:
Dejea, Christine M; Fathi, Payam; Craig, John M et al. (2018) Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science 359:592-597
Staedtke, Verena; Bai, Ren-Yuan; Kim, Kibem et al. (2018) Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564:273-277
Deng, Yang; Tu, Huakang; Pierzynski, Jeanne A et al. (2018) Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. Eur J Cancer 92:20-32
Tamura, Koji; Yu, Jun; Hata, Tatsuo et al. (2018) Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proc Natl Acad Sci U S A 115:4767-4772

Showing the most recent 10 out of 883 publications